Top Markets
Coin of the day
Quantum Genomics S.A. Quantum Genomics S.A.

Quantum Genomics S.A.

ALQGC
Rangering i aksjer #37063
Quantum Genomics S.A., a biopharmaceutical firm established in Paris, France,... Quantum Genomics S.A., a biopharmaceutical firm established in Paris, France, in 2005, focuses on creating treatments for cardiovascular ailments. Its therapeutic approach utilizes the brain aminopeptidase A inhibition (BAPAI) platform, primarily addressing high blood pressure (hypertension) and heart failure. The company's key asset, firibastat, is currently undergoing a crucial Phase III study as a standalone therapy for hypertension and is also in clinical trials for heart failure. Additionally, Quantum Genomics is progressing QGC011 for hypertension in combination therapy, and further developing QGC006 and QGC606 to target both hypertension and heart failure.
Aksjekurs
$0.07600875
Sist synkronisert: 2024-11-20
Markedsverdi
$2.06M
Endring (1 dag)
-0.51%
Endring (1 år)
0.00%
Land
FR
Handel Quantum Genomics S.A. (ALQGC)

Kategori

P/B-forhold for Quantum Genomics S.A. (ALQGC)
P/B-forhold per August 2026 TTM: -2.05
Ifølge Quantum Genomics S.A. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/B-forhold (TTM) -2.05. Ved slutten av 2023 hadde selskapet et P/B-forhold på 8.46.
P/B-historikk for Quantum Genomics S.A. fra 2009 til 2026
P/B-forhold ved hvert års slutt
År P/B-forhold Endre
2026 (TTM) -2.05 -0.18%
2024 -2.05 -124.18%
2023 8.46 649.27%
2022 1.13 -90.55%
2021 11.95 194.68%
2020 4.06 -37.21%
2019 6.46 -8.65%
2018 7.07 87.24%
2017 3.78 -35.35%
2016 5.84 -20.06%
2015 7.31 -103.58%
2014 -204.14 1,261.27%
2013 -15.00 -41.14%
2012 -25.48 74.82%
2011 -14.57 70.19%
2010 -8.56 -101.36%
2009 630.17 0.00%
P/B-forhold for lignende selskaper eller konkurrenter
Selskap P/B-forhold Forskjell i P/B-forhold Land
6.3419 -409.91%
US
6.2413 -404.99%
NL
- -
CH
- -
KR
3.4612 -269.14%
BE